质母细胞瘤的多基因酶治疗:评估Regorafenib的理由
Ana Maria Muñoz-Mármol1, Bárbara Meléndez2, Ainhoa Hernandez3,4,5
1Pathology Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.
Cancers
|February 13, 2025
概括
由于可向瘤变化的低率和血脑屏障透率较低,regorafenib对质母细胞瘤 (GBM) 治疗的潜力有限. 未来的药物开发需要了解目标存在和药物输送,以便有效的GBM治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 质母细胞瘤 (GBM) 是一种具有有限治疗选择的侵袭性脑瘤.
- 雷戈拉菲尼布是一种多酶抑制剂,具有潜在的抗癌活性.
- 了解GBM的遗传情景对于有针对性的治疗选择至关重要.
研究的目的:
- 调查使用雷戈拉费尼布治疗质母细胞瘤的理由.
- 评估与regorafenib相关的GBM患者中可向的基因变异的存在.
- 评估这些改变在血管生成中的影响.
主要方法:
- 在103名新诊断的GBM患者中,对46个蛋白质激酶 (PK) 基因的突变,CNV,融合和过度表达进行了基因组分析.
- 对regorafenib的结合亲和力和对这些PKs的抑制活性进行分析.
- 对血管生成相关基因的功能性丰富分析.
主要成果:
- 虽然70.8%的患者有可向的PK基因的改变,但在46个潜在的目标中,只有33%的患者有潜在的瘤性改变.
- 在临床度下,regorafenib抑制的18个PKs中,46.6%的患者出现了变化,但只有25.2%的患者出现了假定的瘤性变化.
- 大约29.1%的患者在18个基因组或血管生成相关基因中出现了瘤性改变.
结论:
- 很大一部分GBM患者缺乏regorafenib向的关键PKs的假定瘤性变化.
- 由于regorafenib的血脑屏障透能力较差,可能会限制其在GBM治疗中的有效性.
- 未来针对GBM的多向药物策略需要精确了解可向的变化和大脑中适当的药物度.
相关概念视频
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...